Shots:
- Lineagen to receive $9.6M consisting of 6,167,510 shares of Bionano’s common stock, ~ $1.7M in cash and assumption of ~$2.9M in liabilities. The acquisition complements Binano by adding leading cytogeneticists, genetic counselors, laboratory operations and billing experts, clinical commercialization experts, and payor contracts
- The acquisition expands Bionano’s Saphyr genome imaging platform by adding Lineagen’s diagnostics services business based on a menu of LDTs and other services performed in a CLIA-certified environment serving a $1B market
- The addition of Lineagen gives Bionano a unique combination of centralized and decentralized solutions for genomics research and clinical genomics to support revenue growth
Click here to read full press release/ article | Ref: Businesswire | Image: Arup Laboratories
